The use of reduced intensity conditioning (RIC) with alemtuzumab is associated with a higher rate of cytomegalovirus (CMV) reactivation than RIC without alemtuzumab, 1 especially when combined with fludarabine. 2 Alemtuzumab, used as in vivo T-cell depletion, has a long plasma half-life, resulting in prolonged lymphopaenia. In 16 patients receiving allogeneic stem cell transplantation (allo-SCT) with in vivo alemtuzumab, the half-life was estimated at 15-21 days with a median total lymphocyte count (TLC) at 6 months of only 0.5 Â 10 9 /l. 3 Morris et al. 4 reported lympholytic concentrations of alemtuzumab for 56 days after RIC in patients who were treated with 100 mg in vivo alemtuzumab (n ¼ 10). 4 A sustained recovery of median TLC to 41 Â 10 9 /l was reached by 4 months in the myeloablative conditioning (MAC) group but not until 9 months in the RIC group. The higher rate of infective complications (for example, CMV and adenovirus) reported in T-cell-depleted RIC has, therefore, been attributed to delayed immune reconstitution.
Although functional impairment of lymphocytes may persist after TLC recovery, with low B-cell counts and inverted CD4/8 ratios, 5 delayed TLC recovery remains an important prognostic factor for infective complications and treatment outcome. Low TLC at 1 month post transplant is predictive for relapse in acute myeloblastic leukaemia (AML) and acute lymphoblastic leukaemia (ALL). [6] [7] [8] Lower TLC at 6 months is predictive of treatment failure (relapse, death or graft failure) following T-cell-depleted allo-SCT, 9 and lower TLC has also been identified as a risk factor for progressive adenovirus and death after RIC with alemtuzumab. 10 In this study, we compared the post transplant recovery of TLC in patients receiving RIC with in vivo alemtuzumab to those receiving T-cell-replete MAC. Potential confounding variables for slow immune reconstitution were also assessed including the amount of prior therapy, presence of graftversus-host disease (GVHD) and use of post transplant steroid therapy. The impact these factors have on immune function was then assessed, as indicated by the frequency of CMV reactivation and non-CMV viral infections.
We analysed TLC recovery in 50 sequential adult patients with haematological disorders at a single centre between March 2000 and July 2003 (Table 1) . Patients receiving ATG, T-cell-replete RIC or T-cell-depleted MAC using alemtuzumab were excluded. Twenty-seven patients received an RIC with alemtuzumab of whom 26 patients received fludarabine 30 mg/m 2 on days -7 to -3 and melphalan 140 mg/m 2 on day -2. Alemtuzumab was given as either 20 mg/day on days -8 to -4 (n ¼ 19), 20 mg/day on days -8 and -7 (n ¼ 1, due to anaphylactoid reaction to alemtuzumab) or 30 mg/day on days -8 and -7 (n ¼ 7). One patient with intracerebral relapse of AML had cyclophosphamide (CY), 60 mg/kg days -3 and -2; total body irradiation (TBI) 200 cGy single fraction day -1; and alemtuzumab 20 mg/day on days -8 to -4. Twenty-three patients underwent MAC, receiving etoposide 60 mg/kg with TBI (12 or 14.4 Gy), CY 120 mg/kg with TBI (12 or 14.4 Gy) or CY 120 mg/kg with busulphan 16 mg/kg. GVHD prophylaxis was cyclosporine (CYA) for RIC, and CYA alone or with a short course of methotrexate for MAC. TLCs were collected retrospectively at day 0 and then every 30 days until day þ 270. Sequential TLCs were included if within ±7 days of each time point, and 78% (307) were available for analysis. Five variables were tested for their impact on TLC recovery: acute and chronic GVHD, post transplant immunosuppression with steroids (data not shown), number of lines of therapy prior to transplant and use of in vivo alemtuzumab (Figure 1 ). Time to recovery of TLC to 41.0 Â 10 9 /l was then analysed using Cox proportional hazard modelling, censoring at death if before TLC recovery.
Patients were monitored for CMV infection by PCR assay on whole blood collected in EDTA. Pre-emptive therapy with intravenous ganciclovir 5 mg/kg b.d. was commenced when levels exceeded 5000 copies/ml. CMV infection was defined as two sequential positive results by PCR without clinical symptoms or signs. The five variables listed above were tested for their influence on the frequency of CMV reactivation by the w 2 test. Patients were investigated for non-CMV infections as clinically indicated at the time.
Median follow-up was 443 days (range: 18-1542 days). The median age of patients undergoing RIC was 45 years (range: 20-57 years) and for MAC was 33 years (range: 19-51 years). We demonstrate a quicker recovery of median TLC in alemtuzumab-treated patients compared with previous reports, 3, 4 with a sustained TLC41 Â 10 9 /l by 6 months. There was no significant difference in TLC recovery between alemtuzumab-treated RIC and T-cell-replete MAC. Patients receiving 100 mg alemtuzumab did not have slower TLC recovery than those receiving lower doses. Post transplant immunosuppression with steroids, acute GVHD and chronic GVHD did not affect TLC recovery, which was only significantly delayed (P ¼ 0.03) by greater pretransplant therapy (1 vs 2 or more lines of therapy).
The overall rate of CMV infection was 22/50 (44%) with a median reactivation time of 34 days (range: 5-263 days). Although CMV infection was more frequent in the patients receiving alemtuzumab-treated RIC (48 vs 39%), this was not significant (P ¼ 0.52), and no other variable analysed had a significant impact on CMV infection. The serological status of donor and recipient affects the chance of CMV infection. To control this, the 33 patients who were at risk of CMV infection (CMV-seropositive recipient and/or donor) were analysed (0/17 of the low-risk patients had CMV infection). 9/16 (56%) of high-risk MAC patients had CMV infection compared with 13/17 (76%) of high-risk RIC patients and the difference remained insignificant (P ¼ 0.22). Non-CMV viral infections were detected in 9/27 Letter to the Editor RIC patients (HSV 1 and 2, adenovirus, parainfluenza, polyoma and RSV) and 3/23 MAC patients (HSV 1 and 6). The difference was not significant by w 2 analysis (P ¼ 0.09). Reduced intensity conditioning aims to minimize procedure-related toxicity, allowing treatment of higher risk patients due to age or amount of prior therapy (in this series, 63% undergoing RIC had 41 line of therapy vs 26% of MAC). Heavy pretreatment may have been a confounding factor when prolonged lymphopaenia was previously identified following alemtuzumab-treated RIC. Lymphocyte recovery after RIC with alemtuzumab is faster than has been previously reported and is similar to T-cellreplete MAC, with no difference in the rate of CMV infection. The amount of prior therapy had the highest impact on immune reconstitution, and this may become more important with the increasing use of autografts and purine analogues.
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